PL2095822T3 - Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy - Google Patents

Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Info

Publication number
PL2095822T3
PL2095822T3 PL09007549T PL09007549T PL2095822T3 PL 2095822 T3 PL2095822 T3 PL 2095822T3 PL 09007549 T PL09007549 T PL 09007549T PL 09007549 T PL09007549 T PL 09007549T PL 2095822 T3 PL2095822 T3 PL 2095822T3
Authority
PL
Poland
Prior art keywords
peptides
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Application number
PL09007549T
Other languages
English (en)
Polish (pl)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PL2095822T3 publication Critical patent/PL2095822T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
PL09007549T 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy PL2095822T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
EP09007549.0A EP2095822B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
EP06714491A EP1855707B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
PL2095822T3 true PL2095822T3 (pl) 2014-03-31

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
PL09007549T PL2095822T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL10177960T PL2289533T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL06714491T PL1855707T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL10177960T PL2289533T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy
PL06714491T PL1855707T3 (pl) 2005-02-28 2006-02-17 Peptydy epitopowe pochodzące z receptora 1 naczyniowego śródbłonkowego czynnika wzrostu oraz szczepionki zawierające takie peptydy

Country Status (10)

Country Link
US (4) US7919099B2 (enExample)
EP (4) EP2095822B1 (enExample)
JP (3) JP4931154B2 (enExample)
CY (1) CY1112867T1 (enExample)
DK (3) DK2289533T3 (enExample)
ES (3) ES2442294T3 (enExample)
PL (3) PL2095822T3 (enExample)
PT (3) PT2095822E (enExample)
SI (3) SI1855707T1 (enExample)
WO (1) WO2006093030A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139393B (zh) 2002-09-12 2010-11-24 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
SG178793A1 (en) * 2007-02-16 2012-03-29 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ATE319477T1 (de) 1995-08-03 2006-03-15 Univ Leiden Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
US20050130899A1 (en) 2001-12-10 2005-06-16 Kyogo Itoh Tumor antigens
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
CN101139393B (zh) 2002-09-12 2010-11-24 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
DK1855707T3 (da) 2012-07-16
PL1855707T3 (pl) 2012-08-31
US20120294877A1 (en) 2012-11-22
EP1855707A1 (en) 2007-11-21
US7919099B2 (en) 2011-04-05
PT2095822E (pt) 2013-12-09
EP2095822A1 (en) 2009-09-02
SI2289533T1 (sl) 2013-11-29
US20110250219A1 (en) 2011-10-13
JP4931154B2 (ja) 2012-05-16
US8257711B2 (en) 2012-09-04
JP5789820B2 (ja) 2015-10-07
EP2289532A1 (en) 2011-03-02
JP2008531463A (ja) 2008-08-14
HK1152873A1 (en) 2012-03-16
JP2010265269A (ja) 2010-11-25
US8663647B2 (en) 2014-03-04
DK2095822T3 (da) 2014-01-13
DK2289533T3 (da) 2013-12-02
WO2006093030A1 (en) 2006-09-08
HK1133601A1 (en) 2010-04-01
JP2012102105A (ja) 2012-05-31
ES2442294T3 (es) 2014-02-11
US20090214581A1 (en) 2009-08-27
PL2289533T3 (pl) 2014-02-28
PT2289533E (pt) 2013-12-10
SI1855707T1 (sl) 2012-07-31
CY1112867T1 (el) 2016-04-13
EP2289533A1 (en) 2011-03-02
ES2385396T3 (es) 2012-07-24
EP2095822B1 (en) 2013-10-16
HK1110529A1 (en) 2008-07-18
EP1855707B1 (en) 2012-04-04
US20140186381A1 (en) 2014-07-03
EP2289533B1 (en) 2013-09-18
PT1855707E (pt) 2012-05-25
JP4843095B2 (ja) 2011-12-21
SI2095822T1 (sl) 2013-12-31
ES2435650T3 (es) 2013-12-20

Similar Documents

Publication Publication Date Title
IL178070A (en) Antibiotic p-selectin antibodies and pharmaceuticals that include them
EP1819358A4 (en) ANTIBODIES TO VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR-1
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
IL230645A (en) Antibodies against activin a or b and their use to promote bone growth
GB2463586B (en) li-key/antigenic epitope hybrid peptide vaccines
PT2272873E (pt) Anticorpos contra o receptor humano de um factor de crescimento i semelhante a insulina e as suas aplicações
IL182267A0 (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor
GB0425546D0 (en) Spinal prostheses
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
SI1855707T1 (sl) Peptidi epitopov izpeljani iz receptorja vaskularnega endotelijskega rastnega faktorja in cepiva ki vsebujejo te peptide
EP1760098A4 (en) BIOCOMPATIBLE MATERIAL
IL188153A0 (en) Supravalent peptide compounds and processor for the preparation thereof
IL212046A0 (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
ZA200708905B (en) Bone cement compositions and the like comprising an RNAIII-inhibiting peptide
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
GB0427301D0 (en) Bone support
EP2108698A4 (en) VASCULAR ENDOTHELIAL CELL BINDING PEPTIDE
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
GB2417482B (en) Box or container support
ZA200800566B (en) Therapeutic peptides and vaccines
EP1881843A4 (en) KINASEPEPTIDES AND ANTIBODIES
PL1874712T3 (pl) Wytwarzanie jodku metylu znakowanego <sup>11</sup>C oraz radioligandu 11C GB67
GB0418390D0 (en) Pot handler & cane support
AU2003214396A1 (en) The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
GB0508752D0 (en) Plant and container support